NN6.F NANOREPRO AG
- Market cap
- EUR 17.5M
- P/E
- -
- P/B
- 0.47x
- ROE
- -5.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2024.
Is NN6.F undervalued?
Graham numberThe Graham number of NANOREPRO AG cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
NANOREPRO AG fundamental analysis
No fundamental analysis for NANOREPRO AG yet.
NANOREPRO AG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About NANOREPRO AG
NanoRepro AG engages in the development, manufacture, and distribution of rapid diagnostic tests and food supplements for home and professional use in Germany and internationally. The company offers products in the areas of family planning, preventive healthcare, intolerances, and infectious diseases. It also develops and commercializes immunochromatographic lateral flow tests; and point of care testing for hospitals and medical practices. NanoRepro AG was incorporated in 20…
Full company profileNANOREPRO AG financial statements
NANOREPRO AG annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 163M | 39.0M | 3.25M | 4.65M |
| Gross Profit | 56.6M | 12.3M | 1.89M | 2.95M |
| Operating Income | 39.5M | 5.45M | -4.44M | -3.45M |
| EBITDA | 38.8M | -4.35M | -4.42M | -3.42M |
| Net Income | 29.7M | -3.72M | -4.69M | -2.05M |
| EPS | 2.30 | -0.29 | -0.37 | -0.16 |
| Balance Sheet | ||||
| Total Assets | 79.1M | 49.5M | 41.5M | 39.0M |
| Total Liabilities | 21.5M | 2.04M | 1.08M | 884K |
| Shareholders' Equity | 57.6M | 47.4M | 40.4M | 38.1M |
| Cash & Short-term Investments | 28.0M | 31.3M | 16.6M | 9.10M |
| Cash Flow | ||||
| Operating Cash Flow | 8.21M | 13.1M | -10.3M | 9.86M |
| Capital Expenditure | 1.40K | 3.31M | 0.00 | 403K |
| Free Cash Flow | 8.21M | 9.84M | -10.3M | 9.46M |
| Ratios | ||||
| ROE | 51.6% | -7.9% | -11.6% | -5.4% |
| ROA | 37.6% | -7.5% | -11.3% | -5.2% |
| Net Profit Margin | 18.3% | -9.5% | -144.3% | -44.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
NANOREPRO AG dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jun 16, 2023
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2024 | - | - | - |
| 2023 | EUR 1.93M | 0.15 | - |
| 2022 | EUR 6.45M | 0.50 | - |
| 2021 | - | - | - |
| 2014 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns NANOREPRO AG
- Insiders 1.82%
- Institutions 8.06%
- Public & others 90.12%
- Shares outstanding 12.6M
- Free float 11.4M
NANOREPRO AG company profile
- Company name
- NANOREPRO AG
- Ticker
- NN6.F
- ISIN
- DE0006577109
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 22
- Fiscal year end
- December
- Address
- Untergasse 8, Marburg, Germany, 35037
- Phone
- 49 6421 951449
- Website
- nanorepro.com
About NANOREPRO AG
NanoRepro AG engages in the development, manufacture, and distribution of rapid diagnostic tests and food supplements for home and professional use in Germany and internationally. The company offers products in the areas of family planning, preventive healthcare, intolerances, and infectious diseases. It also develops and commercializes immunochromatographic lateral flow tests; and point of care testing for hospitals and medical practices. NanoRepro AG was incorporated in 2007 and is headquartered in Marburg, Germany.
NANOREPRO AG management
3- Ms. Lisa JungstPresident of the Management Board & CEO
- Mr. Stefan PiehChief Financial Officer
- Mr. Mike EckelMember of Management Board